Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

Chinese journal of cancer

Volumn 35, Issue 1, 2016, Pages 102-

  Kotaka, Masahito ^a   Xu, Ruihua ^a   Muro, Kei ^a   Park, Young Suk ^a   Morita, Satoshi ^a   Iwasa, Satoru ^a   Uetake, Hiroyuki ^a   Nishina, Tomohiro ^a   Nozawa, Hiroaki ^a   Matsumoto, Hiroshi ^a   Yamazaki, Kentaro ^a   Han, Sae Won ^a   Wang, Wei ^a   Ahn, Joong Bae ^a   Deng, Yanhong ^a   Cho, Sang Hee ^a   Ba, Yi ^a   Lee, Keun Wook ^a   Zhang, Tao ^a   Satoh, Taroh ^a   Buyse, Marc E ^a   Ryoo, Baek Yeol ^a   Shen, Lin ^a   Sakamoto, Junichi ^a   Kim, Tae Won ^a   more..

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Bevacizumab; Metastatic colorectal cancer; Randomized phase III clinical trial; Second line therapy; XELIRI

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ANALOGS AND DERIVATIVES; ASIA; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; HUMAN; INTERNATIONAL COOPERATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SECONDARY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; COLORECTAL NEOPLASMS; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LEUCOVORIN; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY;

EID: 85015353604     PISSN: None     EISSN: 1944446X     Source Type: Journal    
DOI: 10.1186/s40880-016-0166-3     Document Type: Article

References (0)